Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022170126 - COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF

Publication Number WO/2022/170126
Publication Date 11.08.2022
International Application No. PCT/US2022/015357
International Filing Date 04.02.2022
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • ADAGIO THERAPEUTICS, INC. [US]/[US]
Inventors
  • WALKER, Laura
  • RAPPAZZO, C., Garrett
  • SAKHARKAR, Mrunal
  • DEVEAU, Laura
  • KAKU, Chengzi, I.
Agents
  • CLARKE, Marcie, B.
  • BENNETT, Coalton, Sundiata
  • BAYNE, Christopher, D.
  • BAI, Mei
  • ALBURGER, James, M.
Priority Data
63/146,09005.02.2021US
63/151,27819.02.2021US
63/181,46729.04.2021US
63/187,98213.05.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
(FR) COMPOSÉS SPÉCIFIQUES À LA PROTÉINE S DU CORONAVIRUS ET LEURS UTILISATIONS
Abstract
(EN) The present disclosure is directed to antibodies and antigen binding fragments thereof having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
(FR) La présente divulgation se rapporte à des anticorps et à leurs fragments de liaison à l'antigène présentant une spécificité de liaison pour la protéine S des coronavirus (CoV-S), telle que la protéine S du coronavirus responsable du SRAS (SARS-CoV-S) ou la protéine S du coronavirus 2 responsable du SRAS (SARS-CoV-2-S), y compris des anticorps neutralisants. Les anticorps et leurs fragments de liaison à l'antigène comprennent les séquences des polypeptides VH, VL et CDR décrites dans la description, et les polynucléotides codant pour ceux-ci. L'invention concerne également des procédés de préparation desdits anticorps anti-CoV-S et de leurs fragments de liaison à l'antigène. D'autres modes de réalisation de la divulgation concernent l'utilisation d'anticorps anti-CoV-S, et de leurs fragments de liaison à l'antigène, pour le diagnostic, l'évaluation et le traitement de maladies et de troubles associés à des coronavirus, ou à leur protéine S, et des conditions dans lesquelles la neutralisation ou l'inhibition des coronavirus, ou de leur protéine S, représenterait un bienfait thérapeutique.
Latest bibliographic data on file with the International Bureau